中外健康文摘
中外健康文摘
중외건강문적
WORLD HEALTH DIGEST
2013年
22期
74-75
,共2页
奥沙利铂%卡培他滨治%化疗%晚期胃癌
奧沙利鉑%卡培他濱治%化療%晚期胃癌
오사리박%잡배타빈치%화료%만기위암
目的观察奥沙利铂联合卡培他滨治疗晚期胃癌的疗效和安全性。方法21例晚期胃癌患者,静脉滴注奥沙利铂130mg/m2,d1;卡培他滨2500 mg/m2,分早晚2次口服,d1-14,21天为1周期。结果21例患者中,CR 2例,PR10例,SD3例,PD6例,近期有效率(CR+PR)为57.1%,中位生存期9个月,中位疾病进展时间为7个月。不良反应为手足综合征、神经毒性,多为Ⅰ-Ⅱ度。结论奥沙利铂联合卡培他滨化疗方案,缓解率高,能提高生活质量,毒副反应小,患者易耐受。
目的觀察奧沙利鉑聯閤卡培他濱治療晚期胃癌的療效和安全性。方法21例晚期胃癌患者,靜脈滴註奧沙利鉑130mg/m2,d1;卡培他濱2500 mg/m2,分早晚2次口服,d1-14,21天為1週期。結果21例患者中,CR 2例,PR10例,SD3例,PD6例,近期有效率(CR+PR)為57.1%,中位生存期9箇月,中位疾病進展時間為7箇月。不良反應為手足綜閤徵、神經毒性,多為Ⅰ-Ⅱ度。結論奧沙利鉑聯閤卡培他濱化療方案,緩解率高,能提高生活質量,毒副反應小,患者易耐受。
목적관찰오사리박연합잡배타빈치료만기위암적료효화안전성。방법21례만기위암환자,정맥적주오사리박130mg/m2,d1;잡배타빈2500 mg/m2,분조만2차구복,d1-14,21천위1주기。결과21례환자중,CR 2례,PR10례,SD3례,PD6례,근기유효솔(CR+PR)위57.1%,중위생존기9개월,중위질병진전시간위7개월。불량반응위수족종합정、신경독성,다위Ⅰ-Ⅱ도。결론오사리박연합잡배타빈화료방안,완해솔고,능제고생활질량,독부반응소,환자역내수。
Objective: To observe the efficacy and side efferts of oxalipatin plus capecitabine for the treatment of ad-vanced gastric cancer Methods: Twenty-one cases of patients . Oxaliplatin was given at a dose of 130mg/m2 by intravenous injection at day 1; Cape citabine was orally given at a dose of 2500 mg/m2, twice a day for two weeks. Twenty-one days was one cycle.Results: Among 21 patients , the response rate (CR+PR) was 57.1% with 2CR, 10PR, 3SD,6PD. MST was 9 months, mttp was 7 months. The major side effects were hand-foot syn-drome in 7(33.3%), newel toxity 12(57.1%), diarrhea 14 .conclusion: oxaplatin cornbined with capecitabine is a good chernother-appy with high clinical remission rate and could signiticartly improve life quality .And side effects could be tolerable.